Skip to content
Life Sciences Series C Founded 2012

Yikon Genomics

Yikon Genomics provides NIPT and liquid biopsy tests using next-generation sequencing. Its proprietary MALBAC-NGS platform enables selective amplification of target DNA, with kits for non-invasive prenatal testing, pre-implantation genetic testing, SNP-based tumor profiling, and HER2/BRCA testing, plus liquid biopsy for personalized cancer therapies. Founded in 2012 in Changping District, China, the company has…

📍 Changping District, China · Genomics,

Funding snapshot

Last roundSeries C
Amount$31M
Date4 November 2019
Total raised$31M
Team size55

About

Yikon Genomics provides NIPT and liquid biopsy tests using next-generation sequencing. Its proprietary MALBAC-NGS platform enables selective amplification of target DNA, with kits for non-invasive prenatal testing, pre-implantation genetic testing, SNP-based tumor profiling, and HER2/BRCA testing, plus liquid biopsy for personalized cancer therapies. Founded in 2012 in Changping District, China, the company has raised $31.3M in Series C funding from investors including 6 Dimensions Capital and Frontline BioVentures. Provider of NIPT and liquid biopsy tests using next-generation sequencing. Its proprietary MALBAC - NGS platform enables selective amplification of target DNA. It currently has kits for non-invasive prenatal testing, pre-implantation genetic testing, SNP-based tumor profiling, HER2 and BRCA testing. In addition, the company also has a liquid biopsy test for enabling targeted personalized cancer therapies.

Business model

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Portfolio of Sequencing-based Diagnostics

Team background

College Wise > Harvard University

Institutional investors

Guangzhou Yuexiu Industrial Investment Fund Management Bank of Communications Zhongyuan Jiupai Fund Jinhe Capital 6 Dimensions Capital Cash Capital TMCP Frontline BioVentures Shengshan Capital

Latest coverage

No articles yet.

Raising like Yikon Genomics?

Analyze your pitch deck before your next raise.

Analyze My Deck →